Ken Griffin Akebia Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 91,800 shares of AKBA stock, worth $182,682. This represents 0.0% of its overall portfolio holdings.
Number of Shares
91,800
Previous 135,100
32.05%
Holding current value
$182,682
Previous $247,000
62.35%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding AKBA
# of Institutions
111Shares Held
55MCall Options Held
554KPut Options Held
246K-
Black Rock Inc. New York, NY11.6MShares$23.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.28MShares$18.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$11.4 Million11.5% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$9.46 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.91MShares$7.79 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $366M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...